ClinicalTrials.gg
CompletedNCT01519700PIONEERUpdated May 6, 2015Results posted

Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim

A Phase 3 interventional study of EP2006 and Filgrastim in Chemotherapy Associated Neutropenia and Breast Cancer, sponsored by Sandoz. Completed at 26 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-06.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing filgrastim in Breast Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Filgrastim · Breast Neoplasms.

Enrollment
10th of 27
218 · median 120
Started
2011
with 1 other
Phase 3
7 of 31
none open now
Registered
23rd of 31
by date

Among the 31 studies testing filgrastim in Breast Neoplasms, this one is the 10th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2011, is one of 7 in phase 3, and was the 23rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 31 studies testing filgrastim in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About filgrastim

Filgrastim: first FDA approval 1991 (NEUPOGEN), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing filgrastim in Breast Neoplasms, or all of them as a file.
02

Study summary

The study will assess the efficacy of EP2006 compared to Filgrastim with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.

03

Conditions studied

  • Chemotherapy Associated Neutropenia
  • Breast Cancer

Keywords

  • Filgrastim
  • G-CSF, neutropenia
  • supportive care
  • breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with proven breast cancer, eligible for or adjuvant myelosuppressive chemotherapy
  2. Women ≥ 18 years of age
  3. Estimated of more than six months

Exclusion criteria

Exclusion Criteria:

  1. Previous or concurrent except non-invasive non-melanoma skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively, and without evidence of recurrence for at least ten years prior to study entry
  2. Any serious illness or medical condition that may interfere with safety, compliance, response to the products under investigation and their evaluation, e.g.:

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    EP2006

    Eligible patients will be teated with EP2006

    Drug: EP2006

  • Active comparator
    Filgrastim

    Eligible patients will be teated with Filgrastim

    Drug: Filgrastim

Interventions

  • DrugEP2006

    Eligible patients will be teated with EP2006

    Also known as: Filgrastim

  • Eligible patients will be teated with Filgrastim

06

What researchers measure

Primary outcomes

  1. Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy

    Mean duration of severe neutropenia, defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5\*10\^9 cells/L)

    Time frame: 21 days (Cycle 1 of chemotherapy treatment)

Secondary outcomes

  1. Incidence of Febrile Neutropenia

    Incidence of febrile neutropenia by duraton within each cycle and across all cycles. Febrile neutropenia is defined as oral temperature greater than or equal 38.3°C while having an Absolute Neutrophil Count \< 0.5\*10\^9 cells/L (both measured on the same day)

    Time frame: 21 weeks/ 6 cycles

  2. Number of Days of Fever

    Number of days of fever by cycle. Fever is defined as oral temperature greater than or equal to 38.3°C.

    Time frame: 21 weeks/ 6 cycles

  3. Depth of Absolute Neutrophil Count Nadir

    Depth of Absolute Neutrophil Count Nadir, defined as the patient's lowest Absolute Neutrophil Count in cycle 1

    Time frame: Cycle 1/ 21 days

  4. Time to Absolute Neutrophil Count Recovery

    Time to Absolute Neutrophil Count recovery, defined as the time in days from Absolute Neutrophil Count nadir until the patient's Absolute Neutrophil Count increases to more or equal to 2\*10\^9 cells/L after the nadir in cycle 1

    Time frame: Cycle 1/ 21 days

  5. Frequency of Infections

    Frequency of infections by cycle and across all cycles

    Time frame: 21 Weeks/ 6 cycles

  6. Incidence of Hospitalizations Due to Febrile Neutropenia

    Incidence of hospitalizations due to Febrile Neutropenia

    Time frame: 21 Weeks/ 6 cycles

07

Results

Posted Apr 7, 2015

Participant flow

The study population consisted of women of 18 years or older with histologically proven breast cancer who were eligible for neoadjuvant or adjuvant treatment with TAC chemotherapy. The study was aimed to randomize a total of 192 patients in approximately 65 centers worldwide.

Participant flow — Overall Study
MilestoneEP2006EP2006 + NeupogenNeupogen + EP2006Neupogen
Started54555554
Treated cycle 1 ep2006535400
Treated cycle 1 neupogen005552
Treated cycle 2 ep2006520550
Treated cycle 2 neupogen052051
Treated cycle 3 ep2006515100
Treated cycle 3 neupogen005451
Treated cycle 4 ep2006510500
Treated cycle 4 neupogen051050
Treated cycle 5 ep2006464900
Treated cycle 5 neupogen004850
Treated cycle 6 ep2006450480
Treated cycle 6 neupogen049049
Completed45494847
Not completed9677
Withdrew: Death1000
Withdrew: Lost to follow-up0011
Withdrew: Physician decision1130
Withdrew: Withdrawal by subject5332
Withdrew: Other reason2204

Outcome measures

PrimaryMean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy

Mean duration of severe neutropenia, defined as the mean number of consecutive days with Grade 4 neutropenia (ANC less than 0.5\*10\^9 cells/L)

Time frame:
21 days (Cycle 1 of chemotherapy treatment)
Reported as:
Mean · Days
Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy
DaysEP2006 + EP2006 & NeupogenNeupogen + Neupogen & EP2006
Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy1.17 ± 1.111.2 ± 1.02
Statistical analysis
  • EP2006 + EP2006 & Neupogen · Mean difference (net): 0.04The one-sided 97.5% Confidence Interval: \[-0.26, ∞).
SecondaryIncidence of Febrile Neutropenia

Incidence of febrile neutropenia by duraton within each cycle and across all cycles. Febrile neutropenia is defined as oral temperature greater than or equal 38.3°C while having an Absolute Neutrophil Count \< 0.5\*10\^9 cells/L (both measured on the same day)

Time frame:
21 weeks/ 6 cycles
Reported as:
Number · participants
Incidence of Febrile Neutropenia
participantsEP2006EP2006 + NeupogenNeupogen + EP2006NeupogenTotal
Cycle 1 - 0 Days duration50495451204
Cycle 1 - 1 Day duration23005
Cycle 1 - 2 Days duration00101
Cycle 2 - 0 Days duration52515551209
Cycle 2 - 1 Day duration01001
Cycle 3 - 0 Days duration51515451207
Cycle 4 - 0 Days duration51515050202
Cycle 5 - 0 Days duration45484850191
Cycle 5 - 1 Day duration01001
Cycle 6 - 0 Days duration43484849188
Cycle 6 - 1 Day duration11002
All Cycles - 0 Days duration49465451200
All Cycles - 1 Day duration36009
All Cycles - 2 Days duration00101
SecondaryNumber of Days of Fever

Number of days of fever by cycle. Fever is defined as oral temperature greater than or equal to 38.3°C.

Time frame:
21 weeks/ 6 cycles
Reported as:
Number · participants
Number of Days of Fever
participantsEP2006EP2006 + NeupogenNeupogen + EP2006NeupogenTotal
Cycle 1 - No39414246168
Cycle 1 - Yes14207
Cycle 2 - No36434446169
Cycle 2 - Yes42006
Cycle 3 - No40444445173
Cycle 3 - Yes01012
Cycle 4 - No40444346173
Cycle 4 - Yes01102
Cycle 5 - No40444345172
Cycle 5 - Yes01113
Cycle 6 - No39444446173
Cycle 6 - Yes11002
SecondaryDepth of Absolute Neutrophil Count Nadir

Depth of Absolute Neutrophil Count Nadir, defined as the patient's lowest Absolute Neutrophil Count in cycle 1

Time frame:
Cycle 1/ 21 days
Reported as:
Mean · 10^9 cells/L
Depth of Absolute Neutrophil Count Nadir
10^9 cells/LEP2006 + EP2006 & NeupogenNeupogen + Neupogen & EP2006Total
Depth of Absolute Neutrophil Count Nadir0.808 ± 1.36940.744 ± 1.29060.776 ± 1.3278
SecondaryTime to Absolute Neutrophil Count Recovery

Time to Absolute Neutrophil Count recovery, defined as the time in days from Absolute Neutrophil Count nadir until the patient's Absolute Neutrophil Count increases to more or equal to 2\*10\^9 cells/L after the nadir in cycle 1

Time frame:
Cycle 1/ 21 days
Reported as:
Median · Days
Time to Absolute Neutrophil Count Recovery
DaysEP2006 + EP2006 & NeupogenNeupogen + Neupogen & EP2006Total
Time to Absolute Neutrophil Count Recovery2.0 (0 to 6)2.0 (0 to 4)2.0 (0 to 6)
SecondaryFrequency of Infections

Frequency of infections by cycle and across all cycles

Time frame:
21 Weeks/ 6 cycles
Reported as:
Number · participants
Frequency of Infections
participantsEP2006 + NeupogenEP2006 & Neupogen + Neupogen & EP2006Total
Cycle 1 - No102104206
Cycle 1 - Yes134
Cycle 2 - No100102202
Cycle 2 - Yes358
Cycle 3 - No102107209
Cycle 3 - Yes101
Cycle 4 - No101104205
Cycle 4 - Yes235
Cycle 5 - No101106207
Cycle 5 - Yes213
Cycle 6 - No102106208
Cycle 6 - Yes112
All Cycles - No9697193
All Cycles - Yes71017
SecondaryIncidence of Hospitalizations Due to Febrile Neutropenia

Incidence of hospitalizations due to Febrile Neutropenia

Time frame:
21 Weeks/ 6 cycles
Reported as:
Number · participants
Incidence of Hospitalizations Due to Febrile Neutropenia
participantsEP2006EP2006 + NeupogenNeupogen + EP2006NeupogenTotal
No50505551206
Yes21014

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EP2006—6/53 (11.3%)50/53 (94.3%)
EP2006 + Neupogen—4/54 (7.4%)51/54 (94.4%)
Neupogen + EP2006—1/55 (1.8%)52/55 (94.5%)
Neupogen—3/52 (5.8%)50/52 (96.2%)
Most frequent serious events
Most frequent serious events
EventEP2006EP2006 + NeupogenNeupogen + EP2006Neupogen
Febrile NeutropeniaBlood and lymphatic system disorders3/534/541/551/52
AnaemiaBlood and lymphatic system disorders0/530/540/551/52
DiarrhoeaGastrointestinal disorders0/530/540/551/52
LeukopeniaBlood and lymphatic system disorders1/530/540/550/52
EmbolismVascular disorders1/530/540/550/52
Hypertensive crisisVascular disorders1/530/540/550/52
Most frequent other events
Showing 10 of 25
Most frequent other events
EventEP2006EP2006 + NeupogenNeupogen + EP2006Neupogen
AlopeciaSkin and subcutaneous tissue disorders41/5344/5443/5543/52
NauseaGastrointestinal disorders29/5333/5432/5537/52
AstheniaGeneral disorders20/5328/5432/5528/52
Bone painMusculoskeletal and connective tissue disorders13/5320/5419/5519/52
FatigueGeneral disorders17/539/5411/5513/52
Decreased AppetiteMetabolism and nutrition disorders8/534/543/5513/52
DiarrhoeaGastrointestinal disorders5/5311/5413/558/52
AnaemiaBlood and lymphatic system disorders6/535/544/5511/52
VomitingGastrointestinal disorders9/5310/5410/559/52
NeutropeniaBlood and lymphatic system disorders5/537/546/556/52

Baseline characteristics

The safety set consists of all patients who received at least one dose of study drug and had at least one post-baseline safety assessment

Age, Continuous
Age, Continuous(years)EP2006EP2006 + NeupogenNeupogen + EP2006NeupogenTotal
Mean51.5 ± 11.1647.5 ± 11.6449.7 ± 11.0546.9 ± 10.9148.9 ± 11.26
Sex: Female, Male
Sex: Female, Male(Participants)EP2006EP2006 + NeupogenNeupogen + EP2006NeupogenTotal
Female53545552214
Male00000
08

Study locations

26 sites
  • Insitut Onkologie a Rehabilitaca na Plesi
    Ves pod Plesi 110, 26204, Czech Republic
  • Semmelweis Egyetem, III. Belgyogyaszati Klinika
    Budapest, 1125, Hungary
  • Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Onkoradiologia
    Budapest, 1145, Hungary
  • DE OEC, Onkologiai Tanszek
    Debrecen, 4032, Hungary
  • Josa Andras Oktato Korhaz Nonprofit Kft
    Nyiregyhaza, 4400, Hungary
  • Fejer Megyei Szent Gyorgy Korhaz, Onkologiai Osztaly
    Szekesfehervar, 8000, Hungary
  • Vas Megyei Markusovszky Korhaz, Onkoradiologiai Osztaly
    Szombathely, 9700, Hungary
  • Daugavpils Regional Hospital
    Daugavpils, 5400, Latvia
  • Institution of the Russian Academy of Medical Sciences Medical Radiology Research Center RAMS
    Moscow, Krasnogorsk district 143423, Russian Federation
  • State Healthcare Institution (SHI) "Leningrad Regional Oncological Dispensary" at the Surgery Department 2
    Kuzmolovsky, Leningrad region 188663, Russian Federation
  • State Medical-Prophylactic Institution SMPI Reginal Clinical Oncological Dispensary
    Chelyabinsk, 454087, Russian Federation
  • State Healthcare Institution (SHI) "Clinical Oncological Dispensary №1" of Healthcare Department of Krasnodar Territory
    Krasnodar, 350040, Russian Federation
  • Institution of the Russian Academy of Medical Sciences Russian Oncology Research Center n.a. N.N.Blochin of RAMS", Surgery Department of the Female Reproductive System Tumors
    Moscow, 115478, Russian Federation
  • Affiliate No1 of State Healthcare Institution (SHI) "Nizhny Novgorod Regional Oncological Dispensary"
    Nizhny Novgorod, 603081, Russian Federation
  • Institution of the Russian Academy of Medical Sciences Medical Radiology Research Center RAMS
    Obninsk, 249036, Russian Federation
  • State Healthcare Institution SHI Pyatigorsk Oncological Dispensary
    Pyatigorsk, 357502, Russian Federation
  • Non-State Healthcare Institution NSHI
    Saint-Petersburg, 195271, Russian Federation
  • Saint-Petersburg State Healthcare Institution (SPb SHI) "City Clinical Oncological Dispensary"
    Saint-Petersburg, 197022, Russian Federation
  • State Healthcare Institution (SHI)"Voronezh Regional Clinical Oncological Dispensary"
    Voronezh, 394000, Russian Federation
  • Fakultna nemocnica Nitra, Oddelenie radioterapie a klinickej onkologie
    Nitra, 95001, Slovakia
  • Communal Institution "Krivorizhskiy oncology dispensary" of Dnipropetrovsk regional Council, Chemotherapy Department
    Kriviy Rig, Dnipropetrovsk region 50048, Ukraine
  • Communal Institution "Dnipropetrovsk Сity multiple-discipline Clinical Hospital 4" of Dnipropetrovsk Regional Council
    Dnipropetrovsk, 49102, Ukraine
  • Medical center of Limited Liability Company "Inter"
    Lugansk, 91000, Ukraine
  • Lviv state oncological regional treatment-and-diagnostics center, Chemotherapy Department
    Lviv, 79031, Ukraine
  • Communal Institution "Odesa regional clinical hospital", Mammology Center
    Odesa, 65025, Ukraine
  • Vinnytsya Regional Clinical Oncological Center, Chemotherapy Department
    Vinnitsya, 21029, Ukraine
09

References and documents

Publications

  • Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, Stiegler G, Singh P, Schwebig A, Kramer S, Harbeck N. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015 Sep;26(9):1948-1953. doi: 10.1093/annonc/mdv281. Epub 2015 Jun 28. PubMed 26122726 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2012
First posted
Jan 27, 2012
Start
Dec 2011
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Apr 7, 2015
Last update
May 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01519700
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Jan 27, 2012
Start date
Dec 2011
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Apr 7, 2015
Last update
May 6, 2015

Study contacts

Sandoz
study chair · Sandoz

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion